- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
- Interventions
- TD-9855, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Droxidopa, Placebo
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- ampreloxetine
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Placebo, Droxidopa
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Droxidopa, Placebo
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- New York, New York • Charlotte, North Carolina • Milwaukee, Wisconsin
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Placebo, Droxidopa
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 23
- States / cities
- Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Interventions
- ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Sun City, Arizona • La Jolla, California • Palo Alto, California + 16 more